INmune Bio Charts Clear Path for Novel Alzheimer's Drug After FDA Alignment

BOCA RATON, FL – February 23, 2026 – In the relentless search for effective Alzheimer's treatments, biotechnology firm INmune Bio (NASDAQ: INMB) has received a significant boost from U.S. regulators for its novel drug candidate, XPro1595. Following a pivotal End-of-Phase 2 meeting, the Food and Drug Administration (FDA) has aligned with the company's strategy to advance XPro1595 into a registrational study for early Alzheimer's disease, specifically targeting patients with biological signs of inflammation.

This development marks a critical validation for a therapeutic approach that steps away from the well-trodden path of targeting amyloid plaques and instead focuses on a different culprit in cognitive decline: neuroinflammation. The company is now preparing to detail its full strategy, from clinical trial design to plans for a global partnership, in an upcoming webinar on February 27, featuring key clinical experts from the recently completed Phase 2 trial.

A New Target: The Inflammation Link

For decades, Alzheimer's research has been largely dominated by the amyloid hypothesis, which posits that the accumulation of amyloid-beta plaques in the brain is the primary driver of the disease. While recently approved anti-amyloid drugs have shown modest benefits, their limitations and side effects have intensified the search for alternative or complementary mechanisms.

INmune Bio's XPro1595 is at the forefront of a different approach, focusing on the role of the innate immune system and chronic inflammation in the brain. The drug is a next-generation inhibitor of tumor necrosis factor (TNF), a powerful inflammatory signaling protein. However, unlike older TNF inhibitors used for autoimmune conditions like rheumatoid arthritis, XPro1595 is highly selective. It is engineered to neutralize only the soluble form of TNF (sTNF), which is known to be pro-inflammatory and neurotoxic, while sparing transmembrane TNF (tmTNF), a form of the protein essential for immune surveillance and nerve cell protection.

By selectively targeting sTNF, XPro1595 aims to quell the chronic neuroinflammation that contributes to synaptic dysfunction and neuronal death in Alzheimer's without compromising the body's beneficial immune functions. This precision is central to the drug's potential efficacy and its promising safety profile.

From Promising Signals to a Clear Regulatory Path

The FDA's positive feedback is built upon the results of the Phase 2 MINDFuL trial, a randomized, placebo-controlled study that enrolled 208 patients with early Alzheimer's disease and biomarkers of inflammation. While the trial did not meet its primary cognitive endpoint across the entire study population, a deeper analysis revealed a crucial and encouraging trend.

In a pre-specified subgroup of 100 patients who had both amyloid pathology and a high inflammatory burden—defined as having two or more biomarkers of inflammation—XPro1595 showed consistent positive signals. This "ADi" (Alzheimer's with Inflammation) population demonstrated a clinical benefit on cognitive tests, along with improvements in neuropsychiatric symptoms like agitation. These clinical observations were supported by biological data showing a reduction in key markers of neuroinflammation and neuronal injury, such as plasma pTau217 and GFAP.

These findings provided a strong rationale for the precision-medicine strategy INmune Bio presented to the FDA. The agency has now aligned on an integrated Phase 2b/3 clinical development plan. The initial Phase 2b portion will enroll approximately 300 biomarker-selected patients for a nine-month evaluation to confirm the efficacy signals. If successful, the trial will expand into a larger Phase 3 registration segment, ultimately enrolling over 1,000 participants for an 18-month period. The FDA also agreed to the use of the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) as the sole primary endpoint, a standard widely accepted in recent Alzheimer's drug approvals.

Differentiating in a Changing Treatment Landscape

The advancement of XPro1595 comes at a transformative moment for Alzheimer's care. The recent approvals of anti-amyloid antibodies have provided the first disease-modifying treatments, but they are not without significant challenges. A primary concern is the risk of amyloid-related imaging abnormalities (ARIA), which involves brain swelling (ARIA-E) or microbleeds (ARIA-H). This side effect requires frequent MRI monitoring and can be a barrier to treatment for many patients, particularly those with certain genetic risk factors.

A standout finding from the MINDFuL trial was the complete absence of ARIA in patients treated with XPro1595. This clean safety profile, even in a population with a high prevalence of the APOE4 gene and baseline microbleeds, represents a major potential advantage. It suggests XPro1595 could offer a safer alternative for patients at high risk for ARIA or could eventually be used in combination with other therapies to enhance efficacy without compounding safety risks.

The Strategic Blueprint for Phase 3 and Beyond

Armed with a clear regulatory path, INmune Bio is executing a two-pronged strategy focused on clinical precision and commercial partnership. The upcoming registrational trial will employ a biomarker-enrichment strategy to enroll the patients most likely to benefit, a personalized approach that the FDA has supported. At the agency's recommendation, the trial will also include an exploratory cohort of non-enriched patients to assess the drug's potential for broader application.

Recognizing the immense financial and logistical demands of a large-scale Phase 3 program and global commercialization, the company has also made its intention to secure a global partnership a central part of its forward-looking plan. This move is typical for a clinical-stage biotech with a promising late-stage asset, as it allows the company to leverage the resources and expertise of a larger pharmaceutical player to accelerate development and maximize patient access worldwide.

The upcoming webinar will feature presentations from internationally recognized Alzheimer's experts and MINDFuL trial investigators Dr. Michael Woodward of Austin Health in Australia and Dr. Sharon Cohen of the Toronto Memory Program in Canada. Their insights will shed further light on the clinical data and the potential impact of an inflammation-targeting therapy for a disease that continues to pose one of the greatest public health challenges of our time.